HRP20030943B1 - Optical resolution of (1-benzyl-4-methylpiperidin-3-yl)-methylamine and the use thereof for the preparation of pyrrolo 2,3-pyrimidine derivatives as protein kinases inhibitors - Google Patents
Optical resolution of (1-benzyl-4-methylpiperidin-3-yl)-methylamine and the use thereof for the preparation of pyrrolo 2,3-pyrimidine derivatives as protein kinases inhibitorsInfo
- Publication number
- HRP20030943B1 HRP20030943B1 HR20030943A HRP20030943A HRP20030943B1 HR P20030943 B1 HRP20030943 B1 HR P20030943B1 HR 20030943 A HR20030943 A HR 20030943A HR P20030943 A HRP20030943 A HR P20030943A HR P20030943 B1 HRP20030943 B1 HR P20030943B1
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- amino
- acylamino
- alkylamino
- group
- Prior art date
Links
- NVKDDQBZODSEIN-UHFFFAOYSA-N 1-benzyl-n,4-dimethylpiperidin-3-amine Chemical compound C1CC(C)C(NC)CN1CC1=CC=CC=C1 NVKDDQBZODSEIN-UHFFFAOYSA-N 0.000 title 1
- 102000001253 Protein Kinase Human genes 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 230000003287 optical effect Effects 0.000 title 1
- 108060006633 protein kinase Proteins 0.000 title 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 9
- 125000004442 acylamino group Chemical group 0.000 abstract 5
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 abstract 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 3
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 abstract 3
- 229910052805 deuterium Inorganic materials 0.000 abstract 3
- -1 hydroxy, amino Chemical group 0.000 abstract 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 125000004423 acyloxy group Chemical group 0.000 abstract 2
- 125000006620 amino-(C1-C6) alkyl group Chemical group 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 102200031660 rs730880032 Human genes 0.000 abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 125000006823 (C1-C6) acyl group Chemical group 0.000 abstract 1
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 abstract 1
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 125000006239 protecting group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29477501P | 2001-05-31 | 2001-05-31 | |
US34104801P | 2001-12-06 | 2001-12-06 | |
PCT/IB2002/001905 WO2002096909A1 (en) | 2001-05-31 | 2002-05-29 | Optical resolution of (1-benzyl-4-methylpiperidin-3-yl) -methylamine and the use thereof for the preparation of pyrrolo 2,3-pyrimidine derivatives as protein kinases inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
HRP20030943A2 HRP20030943A2 (en) | 2005-08-31 |
HRP20030943B1 true HRP20030943B1 (en) | 2011-11-30 |
Family
ID=26968730
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20030943A HRP20030943B1 (en) | 2001-05-31 | 2003-11-19 | Optical resolution of (1-benzyl-4-methylpiperidin-3-yl)-methylamine and the use thereof for the preparation of pyrrolo 2,3-pyrimidine derivatives as protein kinases inhibitors |
Country Status (52)
Families Citing this family (119)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PA8474101A1 (es) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
ATE380031T1 (de) | 1999-12-10 | 2007-12-15 | Pfizer Prod Inc | Pyrrolo 2,3-d pyrimidinderivate enthaltende zusammensetzungen |
HUP0301114A3 (en) * | 2000-06-26 | 2004-11-29 | Pfizer Prod Inc | Pyrrolo[2,3-d]pyrimidine compounds as immunosuppressive agents and pharmaceutical compositions containing them |
GT200200234A (es) | 2001-12-06 | 2003-06-27 | Compuestos cristalinos novedosos | |
TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
JP2006514989A (ja) | 2002-07-29 | 2006-05-18 | ライジェル ファーマシューティカルズ | 2,4−ピリミジンジアミン化合物による自己免疫疾患の治療および予防方法 |
AU2003250197B2 (en) * | 2002-08-27 | 2009-11-12 | Merck Patent Gmbh | Glycinamide derivatives as raf-kinase inhibitors |
PL378246A1 (pl) | 2002-11-26 | 2006-03-20 | Pfizer Products Inc. | Sposób leczenia odrzucania przeszczepu |
AU2004265288A1 (en) | 2003-07-30 | 2005-02-24 | Rigel Pharmaceuticals, Inc. | 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases |
CA2563569A1 (en) * | 2004-05-03 | 2005-11-10 | Novartis Ag | Combinations comprising a s1p receptor agonist and a jak3 kinase inhibitor |
AU2005260032A1 (en) | 2004-06-29 | 2006-01-12 | Amgen Inc. | Pyrrolo[2,3-d]pyrimidines that modulate ACK1 and LCK activity |
WO2006017443A2 (en) | 2004-08-02 | 2006-02-16 | Osi Pharmaceuticals, Inc. | Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds |
KR20070085433A (ko) * | 2004-11-24 | 2007-08-27 | 노파르티스 아게 | Jak 저해제들과 bcr-abl, flt-3, fak 또는raf 키나제 저해제들 중 하나 이상의 조합물 |
AR054416A1 (es) | 2004-12-22 | 2007-06-27 | Incyte Corp | Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas. |
US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
MX286273B (es) | 2005-06-08 | 2011-05-04 | Rigel Pharmaceuticals Inc | Composiciones y metodos para inhibicion de la via jak. |
US8163767B2 (en) | 2005-07-14 | 2012-04-24 | Astellas Pharma Inc. | Heterocyclic Janus Kinase 3 inhibitors |
CN102127078A (zh) | 2005-07-14 | 2011-07-20 | 安斯泰来制药株式会社 | Janus激酶3的杂环类抑制剂 |
MX2008001334A (es) | 2005-07-29 | 2008-03-24 | Pfizer Prod Inc | Derivados de pirrolo [2,3-d]pirimidina, sus intermedios y sintesis. |
US20070149506A1 (en) | 2005-09-22 | 2007-06-28 | Arvanitis Argyrios G | Azepine inhibitors of Janus kinases |
PL2426129T3 (pl) | 2005-12-13 | 2017-04-28 | Incyte Holdings Corporation | Podstawione heteroarylem pirolo[2,3-b]pirydyny i pirolo[2,3-b]pirymidyny jako inhibitory kinazy Janusowej |
JP2009528295A (ja) | 2006-02-24 | 2009-08-06 | ライジェル ファーマシューティカルズ, インコーポレイテッド | Jak経路の阻害のための組成物および方法 |
GB0605691D0 (en) * | 2006-03-21 | 2006-05-03 | Novartis Ag | Organic Compounds |
CA2673038C (en) | 2006-12-22 | 2015-12-15 | Incyte Corporation | Substituted tricyclic heteroaryl compounds as janus kinase inhibitors |
ME00960B (me) | 2007-06-13 | 2012-06-20 | Incyte Corp | Soli inhibitora janus kinaze, (r)-3-(4-(7h-pirol[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)-3-ciklopentilpropannitrila |
CL2008001709A1 (es) | 2007-06-13 | 2008-11-03 | Incyte Corp | Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras. |
WO2009007839A1 (en) * | 2007-07-11 | 2009-01-15 | Pfizer Inc. | Pharmaceutical compositions and methods of treating dry eye disorders |
CN102007124B (zh) | 2008-02-15 | 2014-06-18 | 里格尔制药公司 | 嘧啶-2-胺化合物及其作为jak激酶抑制剂的用途 |
BRPI0909040B8 (pt) | 2008-03-11 | 2021-05-25 | Incyte Holdings Corp | derivados de azetidina e ciclobutano, seus usos, e composição |
AU2009244897B2 (en) | 2008-04-16 | 2014-11-13 | Alexion Pharmaceuticals, Inc. | 2, 6-diamino- pyrimidin- 5-yl-carboxamides as syk or JAK kinases inhibitors |
US8138339B2 (en) | 2008-04-16 | 2012-03-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
AU2009238590A1 (en) | 2008-04-22 | 2009-10-29 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
NZ590922A (en) * | 2008-08-01 | 2012-09-28 | Biocryst Pharm Inc | Piperidine derivatives as jak3 inhibitors |
NZ605292A (en) | 2008-08-20 | 2014-06-27 | Zoetis Services Llc | Pyrrolo[2,3-d]pyrimidine compounds |
US8592415B2 (en) * | 2009-02-11 | 2013-11-26 | Reaction Biology Corp. | Selective kinase inhibitors |
CN102459270B (zh) | 2009-04-20 | 2015-04-29 | 奥斯拜客斯制药有限公司 | Janus激酶3的哌啶抑制剂 |
LT2432472T (lt) | 2009-05-22 | 2020-02-10 | Incyte Holdings Corporation | 3-[4-(7h-pirolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]oktan- arba heptan-nitrilas, kaip jak inhibitoriai |
US8716303B2 (en) | 2009-05-22 | 2014-05-06 | Incyte Corporation | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
US9249145B2 (en) | 2009-09-01 | 2016-02-02 | Incyte Holdings Corporation | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
JP5658756B2 (ja) * | 2009-09-10 | 2015-01-28 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Jakの阻害剤 |
MX2012004180A (es) | 2009-10-09 | 2012-07-17 | Incyte Corp | Derivados de hidroxil, ceto y glucuronido de 3-(4-7h-pirrolo[2,3-d ]pirimidin-a-il)-1h-pirazol-1-il)-3-ciclopentilpropanonitrilo. |
AP2012006192A0 (en) | 2009-10-15 | 2012-04-30 | Pfizer | PyrroloÄ2,3-DÜ pyrimidine compounds. |
CA2782720A1 (en) | 2009-12-18 | 2011-06-23 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidine compounds |
KR20140015162A (ko) * | 2010-01-12 | 2014-02-06 | 에프. 호프만-라 로슈 아게 | 트라이사이클릭 헤테로사이클릭 화합물, 조성물 및 이의 사용 방법 |
US20120309776A1 (en) | 2010-02-05 | 2012-12-06 | Pfitzer Inc. | Pyrrolo[2,3-d]pyrimidine urea compounds as jak inhibitors |
PL3050882T3 (pl) | 2010-03-10 | 2018-08-31 | Incyte Holdings Corporation | Piperydyn-4-ylowe pochodne azetydyny jako inhibitory JAK1 |
BR112012029653B1 (pt) | 2010-05-21 | 2021-01-12 | Incyte Holdings Corporation | formulação farmacêutica para aplicação tópica em pele e seu uso |
US9102625B2 (en) | 2010-11-01 | 2015-08-11 | Portola Pharmaceuticals, Inc. | Nicotinamides as JAK kinase modulators |
CN103415515B (zh) | 2010-11-19 | 2015-08-26 | 因塞特公司 | 作为jak抑制剂的环丁基取代的吡咯并吡啶和吡咯并嘧啶衍生物 |
ES2536415T3 (es) | 2010-11-19 | 2015-05-25 | Incyte Corporation | Pirrolopiridinas y pirrolopirimidinas sustituidas heterocíclicas como inhibidores de JAK |
EP2481397A1 (en) | 2011-01-27 | 2012-08-01 | Ratiopharm GmbH | Pharmaceutical compositions comprising tasocitinib |
EP2481411A1 (en) | 2011-01-27 | 2012-08-01 | Ratiopharm GmbH | Oral dosage forms for modified release comprising the JAK3 inhibitor tasocitinib |
ES2547916T3 (es) | 2011-02-18 | 2015-10-09 | Novartis Pharma Ag | Terapia de combinación de inhibidores de mTOR/JAK |
WO2012135338A1 (en) | 2011-03-28 | 2012-10-04 | Ratiopharm Gmbh | Processes for preparing tofacitinib salts |
US9050342B2 (en) | 2011-03-29 | 2015-06-09 | Pfizer Inc. | Beneficial effects of combination therapy on cholesterol |
AU2012241018B2 (en) | 2011-04-08 | 2015-11-12 | Pfizer Inc. | Crystalline and non- crystalline forms of tofacitinib, and a pharmaceutical composition comprising tofacitinib and a penetration enhancer |
ES2414384T3 (es) | 2011-05-11 | 2013-07-19 | Ratiopharm Gmbh | Composición de liberación modificada que comprende ranolazina |
CA2839767A1 (en) | 2011-06-20 | 2012-12-27 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors |
EP2741747A1 (en) | 2011-08-10 | 2014-06-18 | Novartis Pharma AG | JAK P13K/mTOR COMBINATION THERAPY |
TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
WO2013078466A1 (en) | 2011-11-23 | 2013-05-30 | Portola Pharmaceuticals, Inc. | Pyrazine kinase inhibitors |
CA3131037A1 (en) | 2011-11-30 | 2013-06-06 | Emory University | Antiviral jak inhibitors useful in treating or preventing retroviral and other viral infections |
US10821111B2 (en) | 2011-11-30 | 2020-11-03 | Emory University | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections |
EP2791141B1 (en) | 2011-12-15 | 2017-02-08 | ratiopharm GmbH | Tofacitinib mono-tartrate salt |
US9193733B2 (en) | 2012-05-18 | 2015-11-24 | Incyte Holdings Corporation | Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
WO2014016338A1 (en) | 2012-07-25 | 2014-01-30 | Lek Pharmaceuticals D.D. | New synthetic route for the preparation of 3-amino-piperidine compounds |
US9676756B2 (en) | 2012-10-08 | 2017-06-13 | Portola Pharmaceuticals, Inc. | Substituted pyrimidinyl kinase inhibitors |
HUE055894T2 (hu) | 2012-11-15 | 2021-12-28 | Incyte Holdings Corp | A ruxolitinib nyújtott felszabadulású dózisformái |
WO2014083150A1 (en) * | 2012-11-30 | 2014-06-05 | Lek Pharmaceuticals D.D. | Preparation of 3-amino-piperidine compounds via nitro-tetrahydropyridine precursors |
EP2935216B1 (en) | 2012-12-17 | 2018-06-27 | Sun Pharmaceutical Industries Limited | Process for the preparation of tofacitinib and intermediates thereof |
EP2938616A4 (en) | 2012-12-28 | 2016-06-15 | Glenmark Pharmaceuticals Ltd | PROCESS FOR THE PREPARATION OF TOFACITINIB AND INTERMEDIATES |
ME03301B (me) | 2013-02-22 | 2019-07-20 | Pfizer | Kombinacija pirol0[2,3-d]pirimidinskih derivatas jednim ili više dodatnih sredstava као inhibitori kinaza srodnih janus kinazi (јак) |
BR112015021458B1 (pt) | 2013-03-06 | 2022-06-07 | Incyte Holdings Corporation | "processos e intermediários para preparar {1-{1-[3-flúor2-(trifluormetil)isonicotinoil] piperidin-4-il}-3-[4-(7hpirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]azetidin-3-il}acetonitrila, útil no tratamento de doenças relacionadas com a atividade de janus quinases |
JP6041823B2 (ja) | 2013-03-16 | 2016-12-14 | ファイザー・インク | トファシチニブの経口持続放出剤形 |
US20140343034A1 (en) | 2013-04-25 | 2014-11-20 | Japan Tobacco Inc. | Skin barrier function improving agent |
WO2014174073A1 (en) | 2013-04-26 | 2014-10-30 | Sandoz Ag | Sustained release formulations of tofacitinib |
KR20160045081A (ko) | 2013-08-07 | 2016-04-26 | 인사이트 코포레이션 | Jak1 억제제용 지속 방출 복용 형태 |
CN104513248B (zh) * | 2013-09-30 | 2019-05-24 | 重庆医药工业研究院有限责任公司 | 一种托法替尼中间体的纯化方法 |
PT3318565T (pt) | 2013-12-05 | 2021-05-28 | Pfizer | Pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinilo e pirrolo[2,3-d]piridinilo acrilamidas |
BR112015025543B1 (pt) * | 2013-12-09 | 2020-11-03 | Unichem Laboratories Limited | processo para a preparação de (3r,4r)-(1-benzil-4- metilpiperidina-3-il)-metilamina e compostos intermediários |
US9260438B2 (en) | 2014-02-06 | 2016-02-16 | Apotex Inc. | Solid forms of tofacitinib salts |
US9498467B2 (en) | 2014-05-30 | 2016-11-22 | Incyte Corporation | Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1 |
EP3180344B1 (en) | 2014-08-12 | 2019-09-18 | Pfizer Inc | Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase |
UA118149C2 (uk) * | 2015-01-20 | 2018-11-26 | Вуксі Фортуне Фармасьютікал Ко., Лтд | Інгібітор jak |
BR112017001516B1 (pt) * | 2015-02-17 | 2023-10-31 | Amorepacific Corporation | Método de ressolubilização quiral, estereoisômero, método para preparar um composto, composto, composição, e kit de ressolubilização quiral |
CN104761556B (zh) * | 2015-03-21 | 2017-06-23 | 河北国龙制药有限公司 | 托法替布中间体杂质、托法替布杂质及其合成方法,以及托法替布的质量监控方法 |
EP3078665A1 (en) | 2015-04-10 | 2016-10-12 | OLON S.p.A. | Efficient method for the preparation of tofacitinib citrate |
PL3290418T3 (pl) | 2015-04-29 | 2019-11-29 | Wuxi Fortune Pharmaceutical Co Ltd | Inhibitory kinaz janusowych (jak) |
WO2016178110A1 (en) | 2015-05-01 | 2016-11-10 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl, pyrrolo[2,3-b]pyridinyl acrylamides and epoxides thereof |
UA118822C2 (uk) | 2015-05-29 | 2019-03-11 | Вуксі Фортуне Фармасьютікал Ко., Лтд | Інгібітор янус-кінази |
EP3328360A4 (en) * | 2015-07-27 | 2019-01-02 | Unichem Laboratories Limited | Tofacitinib orally disintegrating tablets |
KR101771219B1 (ko) * | 2015-08-21 | 2017-09-05 | 양지화학 주식회사 | 야누스 키나제 1 선택적 억제제 및 그 의약 용도 |
CN108472298B (zh) | 2015-11-24 | 2021-04-20 | 深圳阿拉丁医疗科技有限公司 | 选择性激酶抑制剂 |
CN105348287A (zh) * | 2015-11-30 | 2016-02-24 | 宁波立华制药有限公司 | 一种枸橼酸托法替布的新型合成工艺 |
KR102565407B1 (ko) * | 2016-01-04 | 2023-08-10 | (주)아모레퍼시픽 | 극성 비양자성 용매를 이용한 n-[4-(1-아미노에틸)-페닐]-술폰아미드 유도체의 카이랄 분할 방법 |
WO2017125417A1 (en) | 2016-01-18 | 2017-07-27 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Tofacitinib as vaccination immune modulator |
CA3025636C (en) | 2016-06-30 | 2022-10-18 | Daewoong Pharmaceutical Co., Ltd. | Pyrazolopyrimidine derivatives as kinase inhibitor |
CN106831538B (zh) * | 2017-01-22 | 2019-06-25 | 苏州楚凯药业有限公司 | 托法替尼中间体的制备方法 |
KR102398659B1 (ko) | 2017-03-17 | 2022-05-16 | 주식회사 대웅제약 | 카이네이즈 저해제로서의 피롤로트리아진 유도체 |
CN107602569A (zh) * | 2017-10-23 | 2018-01-19 | 上海博悦生物科技有限公司 | 一种新型吡咯并[2,3‑d]嘧啶化合物及其合成方法和用途 |
KR102078805B1 (ko) | 2017-11-30 | 2020-02-19 | 보령제약 주식회사 | 토파시티닙을 포함하는 약제학적 조성물 |
AR113922A1 (es) | 2017-12-08 | 2020-07-01 | Incyte Corp | Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas |
RS63515B1 (sr) | 2017-12-28 | 2022-09-30 | Daewoong Pharmaceutical Co Ltd | Derivat oksi-fluoropiperidina kao inhibitor kinaze |
KR102577241B1 (ko) | 2017-12-28 | 2023-09-11 | 주식회사 대웅제약 | 카이네이즈 저해제로서의 아미노-플루오로피페리딘 유도체 |
KR102577242B1 (ko) | 2017-12-28 | 2023-09-11 | 주식회사 대웅제약 | 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체 |
TWI797242B (zh) | 2018-01-30 | 2023-04-01 | 美商英塞特公司 | 製備jak抑制劑之方法及中間物 |
KR20200128657A (ko) * | 2018-01-31 | 2020-11-16 | 티더블유아이 파머수티컬스, 인코포레이티드 | 토파시티닙을 포함하는 국소 제형 |
SG11202009441PA (en) | 2018-03-30 | 2020-10-29 | Incyte Corp | Treatment of hidradenitis suppurativa using jak inhibitors |
KR102131107B1 (ko) * | 2019-01-15 | 2020-07-07 | 주식회사 다산제약 | 3-아미노-피페리딘 화합물의 신규한 제조 방법 |
US20220153743A1 (en) | 2019-03-13 | 2022-05-19 | Intas Pharmaceuticals Ltd. | Process for preparation of tofacitinib and pharmaceutically acceptable salt thereof |
WO2020198583A1 (en) | 2019-03-27 | 2020-10-01 | Insilico Medicine Ip Limited | Bicyclic jak inhibitors and uses thereof |
CN113614069B (zh) * | 2019-04-05 | 2024-05-28 | 柳韩洋行 | 用于制备(3r,4r)-1-苄基-n,4-二甲基哌啶-3-胺或其盐的方法以及使用其制备托法替尼的方法 |
CN114727950A (zh) | 2019-11-14 | 2022-07-08 | 辉瑞大药厂 | 1-(((2s,3s,4s)-3-乙基-4-氟-5-氧代吡咯烷-2-基)甲氧基)-7-甲氧基异喹啉-6-羧酰胺组合及口服剂型 |
KR20210064093A (ko) | 2019-11-25 | 2021-06-02 | 주식회사 대웅제약 | 신규한 트리아졸로피리딘 유도체 및 이를 포함하는 약학 조성물 |
WO2021198980A1 (en) | 2020-04-04 | 2021-10-07 | Pfizer Inc. | Methods of treating coronavirus disease 2019 |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
WO2022194782A1 (en) * | 2021-03-15 | 2022-09-22 | Chiesi Farmaceutici S.P.A. | Heterocyclic derivatives as janus kinase inhibitors |
EP4180042A1 (en) | 2021-11-15 | 2023-05-17 | Sanovel Ilac Sanayi Ve Ticaret A.S. | A film coated tablet comprising micronized tofacitinib |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4814477A (en) * | 1984-10-24 | 1989-03-21 | Oce-Nederland B.V. | Dioxaphosphorinanes, their preparation and use for resolving optically active compounds |
JPH07330732A (ja) * | 1994-06-10 | 1995-12-19 | Kyorin Pharmaceut Co Ltd | 光学活性な3−アミノ−1−ベンジルピペリジン誘導体 |
WO1999065909A1 (en) * | 1998-06-19 | 1999-12-23 | Pfizer Products Inc. | PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS |
WO1999065908A1 (en) * | 1998-06-19 | 1999-12-23 | Pfizer Products Inc. | PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS |
WO2001042246A2 (en) * | 1999-12-10 | 2001-06-14 | Pfizer Products Inc. | PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS |
WO2002000661A1 (en) * | 2000-06-26 | 2002-01-03 | Pfizer Products Inc. | PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS IMMUNOSUPPRESSIVE AGENTS |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6136595A (en) * | 1993-07-29 | 2000-10-24 | St. Jude Children's Research Hospital | Jak kinases and regulations of cytokine signal transduction |
US5389509A (en) * | 1993-10-04 | 1995-02-14 | Eastman Kodak Company | Ultrathin high chloride tabular grain emulsions |
IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
DK0682027T3 (da) * | 1994-05-03 | 1998-05-04 | Ciba Geigy Ag | Pyrrolopyrimidinderivater med antiproliferativ virkning |
US6136596A (en) * | 1995-05-19 | 2000-10-24 | University Of Massachusetts | Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases |
MX9709867A (es) | 1995-06-07 | 1998-03-31 | Pfizer | Derivados de pirimidina condensados con un anillo heterociclico, composiciones que contienen los mismos, y uso de los mismos. |
ES2167586T3 (es) | 1995-07-05 | 2002-05-16 | Du Pont | Pirimidinonas fungicidas. |
PT836605E (pt) | 1995-07-06 | 2002-07-31 | Novartis Ag | Pirrolopirimidinas e processos para a sua preparacao |
AR004010A1 (es) | 1995-10-11 | 1998-09-30 | Glaxo Group Ltd | Compuestos heterociclicos |
CN1168138A (zh) | 1995-11-14 | 1997-12-17 | 法玛西雅厄普约翰公司 | 芳基和杂芳基嘌呤化合物 |
AU1441497A (en) | 1996-01-23 | 1997-08-20 | Novartis Ag | Pyrrolopyrimidines and processes for their preparation |
CH690773A5 (de) | 1996-02-01 | 2001-01-15 | Novartis Ag | Pyrrolo(2,3-d)pyrimide und ihre Verwendung. |
GB9604361D0 (en) | 1996-02-29 | 1996-05-01 | Pharmacia Spa | 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors |
AU1794697A (en) | 1996-03-06 | 1997-09-22 | Novartis Ag | 7-alkyl-pyrrolo{2,3-d}pyrimidines |
AU3176297A (en) | 1996-06-25 | 1998-01-14 | Novartis Ag | Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof |
HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
JP2000515136A (ja) | 1996-07-13 | 2000-11-14 | グラクソ、グループ、リミテッド | プロテインチロシンキナーゼ阻害剤としての二環式ヘテロ芳香族化合物 |
AU720429B2 (en) * | 1996-08-23 | 2000-06-01 | Novartis Ag | Substituted pyrrolopyrimidines and processes for their preparation |
AU4718997A (en) | 1996-11-27 | 1998-06-22 | Pfizer Inc. | Fused bicyclic pyrimidine derivatives |
JP2001509805A (ja) | 1997-02-05 | 2001-07-24 | ワーナー−ランバート・コンパニー | 細胞増殖阻害剤としてのピリド〔2,3−d〕ピリミジンおよび4−アミノピリミジン |
EP0972197A1 (en) * | 1997-03-24 | 2000-01-19 | PHARMACIA & UPJOHN COMPANY | Method for identifying inhibitors of jak2/cytokine receptor binding |
JP2002510687A (ja) | 1998-04-02 | 2002-04-09 | ニューロゲン コーポレイション | アミノアルキル置換ピロロ[2,3−b]ピリジンおよびピロロ[2,3−d]ピリミジン誘導体:crf1レセプタのモジュレータ |
AU4317399A (en) | 1998-05-28 | 1999-12-13 | Parker Hughes Institute | Quinazolines for treating brain tumor |
EP1091739A1 (en) | 1998-06-30 | 2001-04-18 | Parker Hughes Institute | Method for inhibiting c-jun expression using jak-3 inhibitors |
IL141434A0 (en) | 1998-08-21 | 2002-03-10 | Parker Hughes Inst | Quinazoline derivatives |
US6080747A (en) * | 1999-03-05 | 2000-06-27 | Hughes Institute | JAK-3 inhibitors for treating allergic disorders |
GT200200234A (es) | 2001-12-06 | 2003-06-27 | Compuestos cristalinos novedosos | |
AU2005260032A1 (en) * | 2004-06-29 | 2006-01-12 | Amgen Inc. | Pyrrolo[2,3-d]pyrimidines that modulate ACK1 and LCK activity |
-
2002
- 2002-05-23 US US10/154,699 patent/US7301023B2/en not_active Expired - Lifetime
- 2002-05-29 PT PT50154541T patent/PT1666481E/pt unknown
- 2002-05-29 AU AU2002304401A patent/AU2002304401C1/en not_active Expired
- 2002-05-29 KR KR10-2003-7015681A patent/KR20040003037A/ko not_active Application Discontinuation
- 2002-05-29 MX MXPA03011062A patent/MXPA03011062A/es active IP Right Grant
- 2002-05-29 PE PE2002000452A patent/PE20030561A1/es not_active Application Discontinuation
- 2002-05-29 SI SI200231004T patent/SI1666481T1/sl unknown
- 2002-05-29 ES ES05015461T patent/ES2369226T3/es not_active Expired - Lifetime
- 2002-05-29 CA CA002448281A patent/CA2448281C/en not_active Expired - Lifetime
- 2002-05-29 TW TW092133699A patent/TWI316061B/zh not_active IP Right Cessation
- 2002-05-29 EP EP05015454.1A patent/EP1666481B9/en not_active Expired - Lifetime
- 2002-05-29 NZ NZ540332A patent/NZ540332A/en not_active IP Right Cessation
- 2002-05-29 BR BR0209246-8A patent/BR0209246A/pt not_active Application Discontinuation
- 2002-05-29 NZ NZ530380A patent/NZ530380A/en not_active IP Right Cessation
- 2002-05-29 PL PL409305A patent/PL228155B1/pl unknown
- 2002-05-29 EP EP02733058A patent/EP1392694A1/en not_active Withdrawn
- 2002-05-29 HU HU0400152A patent/HU230876B1/hu active Protection Beyond IP Right Term
- 2002-05-29 KR KR1020067001821A patent/KR100869409B1/ko active IP Right Grant
- 2002-05-29 GE GE5361A patent/GEP20063784B/en unknown
- 2002-05-29 IL IL15858802A patent/IL158588A0/xx active IP Right Grant
- 2002-05-29 EA EA200301193A patent/EA007251B1/ru active Protection Beyond IP Right Term
- 2002-05-29 SK SK50033-2011A patent/SK288192B6/sk active Protection Beyond IP Right Term
- 2002-05-29 KR KR1020087018519A patent/KR100926875B1/ko active IP Right Grant
- 2002-05-29 ES ES05015454T patent/ES2393385T3/es not_active Expired - Lifetime
- 2002-05-29 EE EEP200300594A patent/EE05332B1/xx active Protection Beyond IP Right Term
- 2002-05-29 DK DK05015454.1T patent/DK1666481T3/da active
- 2002-05-29 CN CNA028108175A patent/CN1729192A/zh active Pending
- 2002-05-29 KR KR1020067025590A patent/KR20060133117A/ko not_active Application Discontinuation
- 2002-05-29 EP EP05015461A patent/EP1609781B1/en not_active Expired - Lifetime
- 2002-05-29 OA OA1200300308A patent/OA12612A/en unknown
- 2002-05-29 SK SK1465-2003A patent/SK288199B6/sk unknown
- 2002-05-29 RS YU92303A patent/RS52144B/en unknown
- 2002-05-29 TW TW091111480A patent/TWI310384B/zh active
- 2002-05-29 CZ CZ2003-3260A patent/CZ304366B6/cs not_active IP Right Cessation
- 2002-05-29 EA EA200600575A patent/EA012666B1/ru active Protection Beyond IP Right Term
- 2002-05-29 UA UA20031110841A patent/UA80093C2/uk unknown
- 2002-05-29 KR KR1020077025832A patent/KR100868814B1/ko active IP Right Review Request
- 2002-05-29 TN TNPCT/IB2002/001905A patent/TNSN03128A1/fr unknown
- 2002-05-29 WO PCT/IB2002/001905 patent/WO2002096909A1/en active Application Filing
- 2002-05-29 JP JP2003500088A patent/JP4381137B2/ja not_active Expired - Lifetime
- 2002-05-29 PL PL02367945A patent/PL367945A1/xx unknown
- 2002-05-29 AT AT05015461T patent/ATE519741T1/de not_active IP Right Cessation
- 2002-05-30 AR ARP020102017A patent/AR037321A1/es not_active Application Discontinuation
- 2002-05-30 GT GT200200100A patent/GT200200100A/es unknown
- 2002-05-30 MY MYPI20021988A patent/MY129649A/en unknown
- 2002-05-30 UY UY27317A patent/UY27317A1/es not_active Application Discontinuation
- 2002-05-30 PA PA20028546301A patent/PA8546301A1/es unknown
- 2002-05-30 GT GT200200100AK patent/GT200200100AA/es unknown
- 2002-05-31 AP APAP/P/2002/002550A patent/AP1859A/en active
-
2003
- 2003-10-13 IS IS6993A patent/IS3023B/is unknown
- 2003-10-13 CU CU20030229A patent/CU23337B7/es not_active IP Right Cessation
- 2003-10-14 ZA ZA200307982A patent/ZA200307982B/en unknown
- 2003-11-19 HR HR20030943A patent/HRP20030943B1/xx not_active IP Right Cessation
- 2003-11-21 MA MA27410A patent/MA27029A1/fr unknown
- 2003-11-24 NO NO20035201A patent/NO328578B1/no not_active IP Right Cessation
- 2003-11-26 EC EC2003004865A patent/ECSP034865A/es unknown
- 2003-11-27 BG BG108389A patent/BG66489B1/bg unknown
-
2004
- 2004-05-07 AR ARP040101561A patent/AR045680A2/es unknown
- 2004-06-16 US US10/869,101 patent/US7432370B2/en not_active Expired - Lifetime
-
2008
- 2008-03-14 CL CL200800762A patent/CL2008000762A1/es unknown
- 2008-07-16 AU AU2008203170A patent/AU2008203170B2/en active Active
- 2008-07-24 CR CR10177A patent/CR10177A/es unknown
-
2009
- 2009-10-13 NO NO20093135A patent/NO20093135L/no not_active Application Discontinuation
-
2012
- 2012-11-09 CY CY20121101069T patent/CY1113322T1/el unknown
-
2017
- 2017-08-02 NL NL300887C patent/NL300887I2/nl unknown
- 2017-08-08 LT LTPA2017025C patent/LTC1666481I2/lt unknown
- 2017-08-09 LU LU00031C patent/LUC00031I2/fr unknown
- 2017-08-17 BE BE2017C032C patent/BE2017C032I2/fr unknown
- 2017-09-01 CY CY2017028C patent/CY2017028I1/el unknown
- 2017-09-04 FR FR17C1031C patent/FR17C1031I2/fr active Active
- 2017-09-08 NO NO2017047C patent/NO2017047I1/no unknown
-
2019
- 2019-02-19 HU HUS1900008C patent/HUS1900008I1/hu unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4814477A (en) * | 1984-10-24 | 1989-03-21 | Oce-Nederland B.V. | Dioxaphosphorinanes, their preparation and use for resolving optically active compounds |
JPH07330732A (ja) * | 1994-06-10 | 1995-12-19 | Kyorin Pharmaceut Co Ltd | 光学活性な3−アミノ−1−ベンジルピペリジン誘導体 |
WO1999065909A1 (en) * | 1998-06-19 | 1999-12-23 | Pfizer Products Inc. | PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS |
WO1999065908A1 (en) * | 1998-06-19 | 1999-12-23 | Pfizer Products Inc. | PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS |
WO2001042246A2 (en) * | 1999-12-10 | 2001-06-14 | Pfizer Products Inc. | PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS |
WO2002000661A1 (en) * | 2000-06-26 | 2002-01-03 | Pfizer Products Inc. | PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS IMMUNOSUPPRESSIVE AGENTS |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20030943B1 (en) | Optical resolution of (1-benzyl-4-methylpiperidin-3-yl)-methylamine and the use thereof for the preparation of pyrrolo 2,3-pyrimidine derivatives as protein kinases inhibitors | |
RS51574B (sr) | JEDINJENJA PIROLO (2,3-d) PIRIMIDINA | |
RS50236B (sr) | Nukleozidni derivati kao inhibitori rnk-zavisne rnk virusne polimeraze | |
EA200400615A1 (ru) | Производные амидов в качестве ингибиторов гликогенсинтаза-киназы 3-бета | |
RS53627B1 (en) | N- (3-Amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors | |
HUP0301514A2 (hu) | Benzimidazol származékok, elżállításuk és ezeket tartalmazó gyógyszerkészítmények | |
NO20051051L (no) | Derivater av dioksan-2-alkylkarbamater, fremgangsmate for fremstilling derav og anvendelse av de samme i terapeutiske midler | |
MX9202142A (es) | Nuevos derivados de urea, proceso para su preparacion, y composicion farmaceutica que los comprende. | |
BR9810829A (pt) | Composto, processo para preparar o mesmo, composição, uso de um composto ou um sal farmaceuticamente aceitável do mesmo ou uma composição, e, processo de tratamento de uma condição | |
DK1268445T3 (da) | 4-amino-5-cyano-2-anilinopyrimidinderivater og deres anvendelse som inhibitorer af cellecykluskinaser | |
DK1757606T3 (da) | Anvendelse af xanthinderivater som l gemidler samt fremgangsm de til deres fremstilling | |
BR0213790A (pt) | Derivados de aminobenzamida como inibidores de glicogênio sintase cinase 3beta | |
RS51545B (en) | THIAZOL PIRAZOLOPIRAMIDINS AS ANTAGONISTS OF CRF1 RECEPTORS | |
NO931366L (no) | 1,2,4-oksadiazolylfenoksyalkylisoksazoler og deres anvendelse som antivirale midler | |
BR0308145A (pt) | Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto | |
HRP20090127T3 (en) | Carboxamide derivatives as muscarinic receptor antagonists | |
RS49997B (sr) | Derivati piridopiranoazepina, njihovo pripremanje i terapeutska primena | |
HRP20080667T3 (en) | 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline derivatives the treatment of infertility | |
YU46787B (sh) | Derivati heteroaril 3-okso-propan-nitrila i postupak za njihovo dobijanje | |
WO2003045901A3 (en) | Guanidine derivatives | |
BR0209936A (pt) | Composição combinada farmacêutica,e uso de um composto e de um inibidor de cianoguanidina ikk | |
AR041256A1 (es) | Indoles sustituidos en posicion 2,4 y su uso como moduladores de 5-ht6 | |
BR9809047A (pt) | Derivados de isoquinolina substituìda e o uso dos mesmos como anticonvulsivantes | |
HUP0401588A2 (hu) | Rákellenes és proliferáció elleni hatású indeno[1,2-c]pirazol-4-on-származékok és ezeket tartalmazó gyógyszerkészítmények | |
AR041255A1 (es) | Indoles 2,7 sustituidos. metodo de obtencion y su uso como medicamento para trastornos del sistema nervioso. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A1OB | Publication of a patent application | ||
ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
B1PR | Patent granted | ||
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20190507 Year of fee payment: 18 |
|
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20200506 Year of fee payment: 19 |
|
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20210511 Year of fee payment: 20 |
|
PB20 | Patent expired after termination of 20 years |
Effective date: 20220529 |